基本情報
- CAS
749-13-3- 標準SMILES
O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1- InChIKey
GPMXUUPHFNMNDH-UHFFFAOYSA-N- 分子式
- C22H23F4NO2
- 平均分子量
- 409.4 g/mol
- 単同位体質量
- 409.16649162
概要
Trifluperidol is an aromatic ketone.
名称と識別子
- 優先名称
- Trifluperidol
- IUPAC
- 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one
- 現地名
- トリフルペリドール
- 英語名
- trifluperidol
- 分子式
- C22H23F4NO2
- 分子量
- 409.42
名称と別名
Trifluperidol749-13-3McN-JR-2498TrifluperidoloR-2498TrifluperidolumNSC-1709781-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-oneDTXSID4023703R8869Q7R8I1-Butanone, 1-(4-fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)-1-piperidinyl)-1-(4-Fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one
名称をさらに表示
トリフルペリドール4′-フルオロ-γ-[4-ヒドロキシ-4-[3-(トリフルオロメチル)フェニル]ピペリジノ]ブチロフェノントリペリドールプシコペリドール1-(4-フルオロフェニル)-4-[4-ヒドロキシ-4-[3-(トリフルオロメチル)フェニル]-1-ピペリジニル]-1-ブタノン4′-フルオロ-γ-[4-ヒドロキシ-4-[3-(トリフルオロメチル)フェニル]ピペリジン-1-イル]ブチロフェノンサイコペリドール4′-フルオロ-γ-[4-ヒドロキシ-4-(α,α,α-トリフルオロ-m-トリル)ピペリジノ]ブチロフェノン1-(4-フルオロフェニル)-4-{4-ヒドロキシ-4-[3-(トリフルオロメチル)フェニル]ピペリジン-1-イル}ブタン-1-オンtrifluperidol USP/EP/BP1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]butan-1-one4-fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)butyrophenone
物性
構造計算による物性
- XLogP
- 3.5
- 極性表面積
- 40.5 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 7
- 回転可能結合数
- 6
- 重原子数
- 29
- 形式電荷
- 0
- 複雑度
- 537
実験および物理化学的性質
LogP2.27
Human DrugsPharmaceuticals
物理化学的性質
- 沸点
- 515.9 · 515.9±50.0 °C(Predicted)
- 比重(密度)
- 1.2119 · 1.2119 (estimate)
- 酸解離定数(Pka)
- 13.87 · 13.87±0.20(Predicted)
- CAS データベース
- 749 · 749-13-3
化学と産業
薬理情報
ATC Code
N - Nervous system
QN - Nervous system
MeSH Pharmacological Classification
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
用途と製造
Use ClassificationPharmaceuticals
応用分野
使用Trifluperidol is a powerful antipsychotic drug. It enhances the action of soporifics, narcotics, and analgesics. It also possesses anticonvulsant and antiemetic action. It is used in psychoses accompanied by motor and mental excitement, in prolonged attacks of recurrent schizophrenia, in cases accompanied by severe depression and delirium, and in alcoholic psychoses. It surpasses other neuroleptics in terms of its ability to stop minor manic excitement.
サプライヤー11 社
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…